Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - nerlynx
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp4106f4a5a4b46a8c1fb9847b0f08bced
identifier: http://ema.europa.eu/identifier
/EU/1/18/1311/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Nerlynx 40 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-4106f4a5a4b46a8c1fb9847b0f08bced
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/18/1311/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - nerlynx
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
What Nerlynx is Nerlynx contains the active substance neratinib . It belongs to a group of medicines called tyrosine kinase inhibitors used to block cancer cells and treat breast cancer.
What Nerlynx is used for Nerlynx is used for patients who have early stage breast cancer which:
The HER2 receptor is a protein found on the surface of cells in the body. It helps control how a healthy breast cell grows. In HER2-positive breast cancer, the cancer cells have a large amount of HER2 receptors on their surface. This results in the cancer cells dividing and growing faster. Hormone receptors are also proteins expressed inside the cells of some specific tissues. Estrogens and progesterone bind to these proteins and regulate cell activity. In HR-positive breast cancer, tumor cell division and growth can be enhanced by estrogens and/or progesterone.
Before Nerlynx is used, your cancer must have been tested to show it is HR-positive and HER2- positive. You must also have previously been treated with trastuzumab.
How Nerlynx works Nerlynx works by blocking the HER2 receptors on the cancer cells. This helps to stop the cells from dividing and growing.
Do not take Nerlynx
Warnings and precautions Talk to your doctor or pharmacist before taking Nerlynx.
You need to take an anti-diarrhoea medicine when you start Nerlynx Nerlynx can cause diarrhoea early during treatment. You should take an anti-diarrhoea medicine so that your diarrhoea does not become severe, and to prevent you from getting dehydrated during treatment with Nerlynx.
Tests and checks for liver problems Nerlynx can cause changes in liver function these are shown in blood tests. Your doctor will do blood tests before and during your treatment with Nerlynx. Your doctor will stop your treatment with Nerlynx if your liver tests show severe problems.
Children and adolescents Do not use in children under 18 years of age. The safety of Nerlynx and how effective it is has not been studied in this age group.
Other medicines and Nerlynx Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Nerlynx can affect the way some other medicines work. Also some other medicines can affect the way Nerlynx works.
In particular tell your doctor or pharmacist if you are taking any of the following medicines:
rifampicin - a medicine for tuberculosis
carbamazepine, phenobarbital, or phenytoin - medicines for seizures
St John s wort - an herbal product for depression
ketoconazole, voriconazole, itraconazole or fluconazole - medicines for fungal infections
erythromycin or clarithromycin - medicines for bacterial infections
protease inhibitors - antiviral medicines
nefazodone a medicine to treat depression
diltiazem or verapamil - medicines for high blood pressure and chest pain
dabigatran or digoxin - a medicine for heart problems
rosuvastatin a medicine to treat high cholesterolemia
irinotecan a medicine used in colorectal cancers
sulfasalazine an anti-inflammatory intestinal medicine
medicines for stomach problems such as:
lansoprazole, omeprazole or similar medicines called proton pump inhibitors or PPIs are not recommended.
ranitidine, cimetidine or similar medicines called H2 receptor antagonists . Neratinib should be taken 10 hours after the H2-receptor antagonist dosing and at least 2 hours before the next dose of the H2-receptor antagonist
antacid medicines - the dose of these medicines and Nerlynx should be separated by at least 3 hours.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Nerlynx.
Nerlynx with food and drink Do not take grapefruit or pomegranate while you are taking Nerlynx this includes eating them, drinking the juice or taking a supplement that might contain them. This is because these fruits may interact with Nerlynx and affect how the medicine works.
Pregnancy If you are pregnant, the doctor will assess the potential benefit to you and the risk to the foetus before giving this medicine to you. If you become pregnant while taking this medicine, the doctor will assess the potential benefit to you and the risk to the foetus, of continuing treatment with this medicine.
Contraception Women who can become pregnant must use an effective method of contraception, including a barrier method:
Men must use an effective barrier method of contraception such as a condom:
Breast-feeding Talk to your doctor before taking Nerlynx if you are breast-feeding or plan to breast-feed because small amounts of this medicine may pass into your breast milk. Your doctor will discuss with you the benefits and risks of taking Nerlynx during this time.
Driving and using machines Nerlynx has minor influence on the ability to drive and use machines. The side effects of Nerlynx (for example, dehydration and dizziness resulting from diarrhoea, fatigue, and fainting) may affect how tasks that require judgment, motor or cognitive skills are carried out.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much Nerlynx to take The recommended dose of Nerlynx is 6 tablets once a day (a total of 240 mg).
The course of treatment is one year.
You need to take an anti-diarrhoea medicine when you start Nerlynx Nerlynx can cause diarrhoea early during treatment unless anti-diarrhoea medicine is taken to prevent or reduce diarrhoea. Diarrhoea usually happens early in treatment with Nerlynx and may be severe, causing you to get dehydrated.
If you take more Nerlynx than you should, contact a doctor or a hospital straight away. Take the medicine pack with you. Some side effects associated with taking more Nerlynx than you should are: diarrhoea, nausea, vomiting and dehydration.
If you forget to take Nerlynx
If you stop taking Nerlynx
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:
Diarrhoea Nerlynx can cause diarrhoea early during treatment unless anti-diarrhoeal medicines are taken to prevent or reduce diarrhoea. The diarrhoea may be severe, and you may get dehydrated. See section 3 for more information about the anti-diarrhoea medicine you need to take at the same time as Nerlynx.
Talk to your doctor if:
Liver problems Nerlynx can cause changes in liver function - these are shown in blood tests. You may or may not have signs or symptoms of liver problems (e.g., yellow skin and/or eyes, dark urine, or light-colour stools). Your doctor will do blood tests before and during your treatment with Nerlynx. Your doctor will stop your treatment with Nerlynx if your liver tests show severe problems.
Other side effects Tell your doctor or pharmacist if you notice any of the following side effects:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Tell your doctor or pharmacist if you notice any of the side effects above.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date refers to the last day of that month.
This medicinal product does not require any special temperature storage conditions. Keep the bottle tightly closed in order to protect from moisture.
Do not use Nerlynx if you notice any signs of damage to the packaging or if there are any signs of tampering (e.g., inner seal is broken).
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Nerlynx contains
The active substance is neratinib. Each film-coated tablet contains neratinib maleate, equivalent to 40 mg neratinib.
The other ingredients are:
Tablet core: mannitol (E421), microcrystalline cellulose, crospovidone, povidone, colloidal anhydrous silica, magnesium stearate
Tablet coating: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, iron oxide red (E172)
What Nerlynx looks like and contents of the pack The film-coated tablets are red oval shaped and debossed with W104 on one side and plain on the other side.
Nerlynx film-coated tablets are packaged in a white, high-density polyethylene (HDPE) round bottle with child-resistant, polypropylene closure, and foil induction inner seal for a tamper-evident seal. Each bottle contains 180 film-coated tablets.
An HDPE desiccant canister with 1 g silica gel is enclosed with the tablets in each bottle. Do not swallow the desiccant. Keep it inside the bottle.
Marketing Authorisation Holder
PIERRE FABRE MEDICAMENT Les Cauquillous 81500 Lavaur France
Manufacturer Pierre Fabre M dicament Production Cahors Site de Cahors Le Payrat 46000 Cahors France
This leaflet was last revised in MM/YYYY
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-4106f4a5a4b46a8c1fb9847b0f08bced
Resource Composition:
Generated Narrative: Composition composition-en-4106f4a5a4b46a8c1fb9847b0f08bced
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1311/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - nerlynx
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp4106f4a5a4b46a8c1fb9847b0f08bced
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp4106f4a5a4b46a8c1fb9847b0f08bced
identifier:
http://ema.europa.eu/identifier
/EU/1/18/1311/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Nerlynx 40 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en